[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100608165":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":21,"centralContacts":25,"locations":34,"responsibleParty":51,"collaborators":20,"id":53,"slug":20,"hasResults":54,"nctId":55,"briefTitle":56,"officialTitle":57,"acronym":20,"eligibilityCriteria":58,"healthyVolunteers":54,"sex":59,"minAge":60,"maxAge":61,"enrollmentInfo":62,"targetDuration":20,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":72,"overallStatus":76,"whyStopped":20,"lastUpdateSubmitDate":77,"lastUpdatePostDateStruct":78,"startDateStruct":81,"completionDateStruct":83,"leadSponsor":85,"locationsCount":86},{"fullName":5,"class":6},"The Miriam Hospital","OTHER",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"2-HOBA Supplementation for Elevated Lipoprotein(a)","EXPERIMENTAL","Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine) at a dose of 400 mg three times daily with meals for 6 weeks.",[13],"Dietary Supplement: 2-HOBA (Hobamine)",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DIETARY_SUPPLEMENT","2-HOBA (Hobamine)","Participants will take oral 2-hydroxybenzylamine (2-HOBA, Hobamine), a dietary supplement with Generally Recognized as Safe (GRAS) status. The study dose is 400 mg three times daily with meals for 6 weeks.",[9],null,[22],{"name":23,"affiliation":5,"role":24},"Wenliang Song, MD","PRINCIPAL_INVESTIGATOR",[26,30],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},"CONTACT","4014449851","wsong@brownhealth.org",{"name":31,"role":27,"phone":32,"phoneExt":20,"email":33},"Daria Salamevich","4014449857","dsalamevich@brownhealth.org",[35],{"facility":36,"status":20,"city":37,"state":38,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"Lipid Clinic at Brown University Health","Providence","Rhode Island","02914","United States","US",{"type":43,"coordinates":44},"Point",[45,46],-71.41283,41.82399,{"lat":46,"lon":45},[49,50],{"name":23,"role":27,"phone":28,"phoneExt":20,"email":29},{"name":23,"role":24,"phone":20,"phoneExt":20,"email":20},{"type":52,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100608165",false,"NCT07198009","2-HOBA Supplementation in People With Elevated Lipoprotein(a)","Modulation of Bioactive Lipids in Lipid Disorders: a Pilot Study of 2-HOBA Supplementation in Individuals With Elevated Lipoprotein(a)","Inclusion Criteria:\n\n* Males and females aged 18-69 years.\n* Elevated Lp(a) levels ≥ 90 mg\u002FdL.\n* Able to provide informed consent and adhere to study schedules.\n* Willing to follow a physician-recommended diet during the study.\n\nExclusion Criteria:\n\n* Pregnant, planning pregnancy during the study period, or currently breastfeeding.\n* Individuals with established cardiovascular disease\n* Planning major changes in diet or exercise routines.\n* Experienced \\>20% weight change in the past 3 months.\n* Diagnosed with malabsorption syndrome or chronic diarrhea.\n* Abnormal liver, kidney, or thyroid function.\n* Drug or alcohol abuse within the past 6 months, or significant mental\u002Fpsychological impairment.\n* Have known bleeding disorders (e.g., hemophilia).\n* Planned surgery during the study period.\n* Donated blood within the last 2 weeks or planning to donate during the study.\n* Require regular blood transfusions.","ALL","18 Years","69 Years",{"count":63,"type":64},10,"ESTIMATED","INTERVENTIONAL",[67],"NA","The goal of this clinical trial is to learn if a natural supplement called 2-hydroxybenzylamine (2-HOBA) can reduce harmful oxidized lipids and improve the function of lipoprotein(a) in adults with high lipoprotein(a) levels.\n\nThe main questions it aims to answer are:\n\nDoes 2-HOBA lower oxidized phospholipids on lipoprotein(a)? Does 2-HOBA reduce markers of inflammation and blood clotting in the blood?\n\nParticipants will:\n\nTake 2-HOBA capsules (400 mg, three times daily with meals) for 6 weeks Provide blood and urine samples at the beginning, middle, and end of the study Have lab tests to measure changes in lipids, inflammation, and clotting markers",[70,71],"Hyperlipidemia","Elevated Lp(a)",[73,74,75],"Oxidized Phospholipids","lp(a)","2HOBA","NOT_YET_RECRUITING","2025-09-25",{"date":79,"type":80},"2025-09-30","ACTUAL",{"date":82,"type":64},"2025-11-01",{"date":84,"type":64},"2026-11",{"name":5,"class":6},1]